tbuckley/cabot-search huggingface dataset:
M10 Living with relapsing polychondritis; a patient and carer engagement exploration
Authors: J Haines, J Hull, J Swaison, T Clark, R Niven
Journal: Thorax (2016)

<h3>Introduction</h3> Relapsing polychondritis (RP) is a poorly understood rare condition in which recurrent bouts of inflammation affect the cartilage of the ears, nose, larynx and tracheobronchial tree. Prospective research is extremely limited and true prevalence data unknown. There are no identified optimal diagnostic pathways and treatment is not standardised. Seeking patient experience and opinion is invaluable to support and inform clinical and research strategies. We report the first known public involvement data relating to living with RP. <h3>Method</h3> The RP patient support group hosted a patient engagement event to provide a reciprocal education environment for healthcare professionals, sufferers and their carers. A one-hour patient and carer focus group, aiming to identify key issues relating to living with RP, was facilitated by members of the Large Airway Collapse with Symptoms (LACS) national network. The facilitators were experienced in running focus groups and had clinical awareness of RP to support discussion when needed. The semi-structured session explored: symptoms; effect on everyday life (emotional, physical, impact on others); diagnosis(time span, professionals involved, ongoing monitoring); healthcare professional support. The session concluded with a priority exercise where participants received four ‘resource’ coins to distribute as they wished to themed issues (as defined collectively by the group). <h3>Results</h3> Twenty-two participated; 13 RP suffers and 9 carers. The group fully engaged and there were no conflicts, despite differing opinions. Despite some valued on-line peer support groups general consensus was provision is limited for those living with RP; the majority had never met another RP sufferer/carer until the session. Group defined themed issues for RP suffers included: lack of understanding; loss of identity; breathlessness; pain; fatigue; impact on relationships; memory impedance. Carer themed issues were similar: pain; lack of appropriate support; restrictions on planning ahead; impact on social life. The allocation of resource across the groups differed in priority (Table 1). <h3>Conclusion</h3> Common issues effect both RP suffers and their carers but there are variations in the hierarchy of burden. We acknowledge this is a preliminary engagement exercise. However, the key issues identified should form the foundation for further research focus groups to guide appropriate patient-centred care for RP.
Treatment Results and Malignant Complications in Patients on Long-Term Treatment with Tyrosine Kinase Inhibitors(TKIs) for Chronic Myeloid Leukemia(CML)
Authors: Taiichi Kyo, Kouhei Kyo, Takesi Okatani, Mitsuhiro Itagaki, Ryouta Imanaka, Yuuta Katayama, Kouji Iwato, Hideki Asaoku, Tetsurou Ohti, Megu Ohtaki, Keiko Ohtani
Journal: Blood (2012)
Favourable Treatment Outcome in Childhood AML Is Determined by Intact Apoptosis Signalling in Myeloid Leukaemia Cells.
Authors: Lüder H. Meyer, Manon Dammé, Sarah M. Eckhoff, Ursula Creutzig, Dirk Reinhardt, Leonid Karawajew, Wolf D. Ludwig, Karsten Stahnke, Klaus M. Debatin
Journal: Blood (2007)
Understanding the Molecular Mechanisms of the Interplay Between Herbal Medicines and Gut Microbiota
Authors: Jun Xu, Hu‐Biao Chen, Song‐Lin Li
Journal: Medicinal Research Reviews (2017)

Herbal medicines (HMs) are much appreciated for their significant contribution to human survival and reproduction by remedial and prophylactic management of diseases. Defining the scientific basis of HMs will substantiate their value and promote their modernization. Ever-increasing evidence suggests that gut microbiota plays a crucial role in HM therapy by complicated interplay with HM components. This interplay includes such activities as: gut microbiota biotransforming HM chemicals into metabolites that harbor different bioavailability and bioactivity/toxicity from their precursors; HM chemicals improving the composition of gut microbiota, consequently ameliorating its dysfunction as well as associated pathological conditions; and gut microbiota mediating the interactions (synergistic and antagonistic) between the multiple chemicals in HMs. More advanced experimental designs are recommended for future study, such as overall chemical characterization of gut microbiota-metabolized HMs, direct microbial analysis of HM-targeted gut microbiota, and precise gut microbiota research model development. The outcomes of such research can further elucidate the interactions between HMs and gut microbiota, thereby opening a new window for defining the scientific basis of HMs and for guiding HM-based drug discovery.
Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-/radio-therapy for glioma
Authors: Hongmei Liu, Yandong Xie, Yafei Zhang, Yifan Cai, Baiyang Li, Honglin Mao, Yingguo Liu, Jun Lu, Longzhen Zhang, Rutong Yu
Journal: Biomaterials (2017)
P1.01-030 Factors Associated with Margin Positive Resections for Non-Small Cell Lung Cancer (NSCLC) in the Mid-South Region of the US
Authors: Yu-Sheng Lee, Matthew Smeltzer, Nicholas Faris, Meredith Ray, Carrie Fehnel, Cheryl Houston-Harris, Meghan Meadows, Paul Levy, Chris Mutrie, Brad Wolf, Lawrence Deese, Lynn Wiggins, Vishal Sachdev, Sam Signore, Edward Robbins, Raymond Osarogiagbon
Journal: Journal of Thoracic Oncology (2017)
PUB126 The Retrospective Analysis of Asymptomatic Lung Cancer Patients Diagnosed Incidentally
Authors: Ayse Ergonul, Tevfik Akcam, Ali Ozdil, Onder Kavurmacı, Kutsal Turhan, Ufuk Cagırıcı, Alpaslan Cakan
Journal: Journal of Thoracic Oncology (2017)
MA04.07 Impact of Major Co-Mutations on the Immune Contexture and Response of KRAS-Mutant Lung Adenocarcinoma to Immunotherapy
Authors: Ferdinandos Skoulidis, Yasir Elamin, Vassiliki Papadimitrakopoulou, Pan Tong, Jing Wang, Jeff Lewis, Waree Rinsurongkawong, Caleb Chu, Emily Roarty, Jianjun Zhang, Hai Tran, Jaime Rodriguez-Canales, Edwin Parra, Carmen Behrens, Humam Kadara, Ignacio Wistuba, John Heymach
Journal: Journal of Thoracic Oncology (2017)
P3.02c-079 Immunotherapy in Non-Small Cell Lung Cancer (NSCLC): Biomarkers Associated with Early Death
Authors: Jacobo Muñoz Del Toro, Eugenia Olmedo, Ana Gomez, Ainhoa Madariaga, Josefa Perez Templado, Luis Gorospe, Pablo Reguera, Ainara Soria, María Gión, Olga Martínez, Javier Molina, María Villamayor, Cristina Saavedra, Gema Muñoz, Victor Albarrán, Amparo Benito, Arantzazu Barquin, Alberto Cabañero, Teresa Alonso, Pablo Gajate, Enrique Grande, Pilar Garrido
Journal: Journal of Thoracic Oncology (2017)
Potassium Sensing by Renal Distal Tubules Requires Kir4.1
Authors: Catherina A. Cuevas, Xiao-Tong Su, Ming-Xiao Wang, Andrew S. Terker, Dao-Hong Lin, James A. McCormick, Chao-Ling Yang, David H. Ellison, Wen-Hui Wang
Journal: Journal of the American Society of Nephrology (2017)

The mammalian distal convoluted tubule (DCT) makes an important contribution to potassium homeostasis by modulating NaCl transport. The thiazide-sensitive Na + /Cl − cotransporter (NCC) is activated by low potassium intake and by hypokalemia. Coupled with suppression of aldosterone secretion, activation of NCC helps to retain potassium by increasing electroneutral NaCl reabsorption, therefore reducing Na + /K + exchange. Yet the mechanisms by which DCT cells sense plasma potassium concentration and transmit the information to the apical membrane are not clear. Here, we tested the hypothesis that the potassium channel Kir4.1 is the potassium sensor of DCT cells. We generated mice in which Kir4.1 could be deleted in the kidney after the mice are fully developed. Deletion of Kir4.1 in these mice led to moderate salt wasting, low BP, and profound potassium wasting. Basolateral membranes of DCT cells were depolarized, nearly devoid of conductive potassium transport, and unresponsive to plasma potassium concentration. Although renal WNK4 abundance increased after Kir4.1 deletion, NCC abundance and function decreased, suggesting that membrane depolarization uncouples WNK kinases from NCC. Together, these results indicate that Kir4.1 mediates potassium sensing by DCT cells and couples this signal to apical transport processes.
A phase II randomized trial of anastrozole (A) and fulvestrant (F) as consolidation therapy in postmenopausal women with advanced non-small cell lung cancer who have received first-line platinum-based chemotherapy with or without bevacizumab.
Authors: B. T. McLaughlin, S. Land, A. A. Tarhini, J. Siegfried, A. Argiris
Journal: Journal of Clinical Oncology (2011)

TPS212 Background: Estrogen may play an important role in the pathogenesis of non-small cell lung cancer (NSCLC), especially in women. Preclinical studies have shown that estrogen can modulate gene expression important in cell proliferation in NSCLC cells. The estrogen receptor has been identified on NSCLC cells and a functional aromatase enzyme is present in 86% of NSCLC. In women over 65, lower levels of aromatase expression in NSCLC tumors was associated with improved survival. Treatment with estrogen plus progestin in postmenopausal women increased the number of deaths from NSCLC. A phase I study combining fulvestrant and gefitinib in women with NSCLC showed the combination was well-tolerated and demonstrated antitumor activity. There is a need for further studies of consolidation/maintenance therapy in patients with advanced NSCLC who have received induction therapy. Methods: We designed a phase II randomized trial of post-induction consolidation treatment in postmenopausal women with advanced NSCLC. Eligible patients have an objective response or stable disease after 6 cycles of first-line platinum-based chemotherapy (carboplatin + gemcitabine, paclitaxel or pemetrexed +/- bevacizumab). 100 patients will be randomized (3 to 1 ratio) to receive either AF and best supportive care (BSC) or BSC alone. AF treatment consists of anastrozole 1 mg by mouth once daily and fulvestrant 250 mg intramuscular monthly after a loading dose of 500 mg on day 1 and 250 mg on day 14 of cycle 1, repeated every 4 weeks until disease progression. Concurrent use of bevacizumab is allowed in both arms. This provides 80% power for the primary comparison of progression-free survival (PFS) at the 0.05 significance level, projecting an improvement in median PFS from 3 months in the BSC arm to 5.7 months in the AF arm. We plan to measure the plasma levels of 17b-estradiol, vascular endothelial growth factor (VEGF), E-selectin, thrombospondin-1 and insulin growth factor (IGF)-1 and baseline tumor tissue expression of ERa, ERb, PR, VEGF, and aromatase to correlate with efficacy parameters.
P3.03-063 Phase 1/2 Trial of WT1 TCR-Transduced Central Memory and Naïve CD8+T Cells for Patients with Mesothelioma and Non-Small Cell Lung Cancer
Authors: Sylvia Lee, Aude Chapuis, Thomas Schmitt, Bernardo Goulart, Megan Mcafee, Maurizio Perdicchio, Cecilia Yeung, Hieu Nguyen, Felecia Wagener, Daniel Hunter, Kieu-Thu Bui, Judy Delismon, Natalie Duerkopp, Phil Greenberg
Journal: Journal of Thoracic Oncology (2017)
Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression
Authors: G Barisione, M Fabbi, G Cutrona, L De Cecco, S Zupo, B Leitinger, M Gentile, M Manzoni, A Neri, F Morabito, M Ferrarini, S Ferrini
Journal: Blood Cancer Journal (2017)

Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression
A Novel View of Paroxysmal Nocturnal Hemoglobinuria (PNH) Pathogenesis: Do Pathologic PNH Hematopoietic Stem/Progenitor Cells (HSPCs) Displace Normal HSPCs From Their Niches in Bone Marrow Because They Are More Motile Due to Defective Adhesion and Enhanced Migratory Properties?
Authors: Janina Ratajczak, Rui Liu, Nagendra Natarajan, Jaroslaw P. Maciejewski, Vivek R. Sharma, Mariusz Z Ratajczak
Journal: Blood (2011)
P1.05-054 Adjuvant Chemotherapy Uptake in Patients with NSCLC after Complete Resection: Single Institution/Single Area Experience
Authors: Vitezslav Kolek, Ivona Grygarkova, Juraj Kultan, Petr Jakubec, Marek Szkorupa, Jiri Klein, Cestmir Neoral, Josef Skarda, Tomas Tichy, Zdenek Kolar
Journal: Journal of Thoracic Oncology (2017)
Complete attenuation of genetically engineered <i>Plasmodium falciparum</i> sporozoites in human subjects
Authors: James G. Kublin, Sebastian A. Mikolajczak, Brandon K. Sack, Matt E. Fishbaugher, Annette Seilie, Lisa Shelton, Tracie VonGoedert, Melike Firat, Sara Magee, Emma Fritzen, Will Betz, Heather S. Kain, Dorender A. Dankwa, Ryan W. J. Steel, Ashley M. Vaughan, D. Noah Sather, Sean C. Murphy, Stefan H. I. Kappe
Journal: Science Translational Medicine (2017)

Immunization of humans with whole sporozoites confers complete, sterilizing immunity against malaria infection. However, achieving consistent safety while maintaining immunogenicity of whole parasite vaccines remains a formidable challenge. We generated a genetically attenuated Plasmodium falciparum (Pf) malaria parasite by deleting three genes expressed in the pre-erythrocytic stage (Pf p52-/p36-/sap1-). We then tested the safety and immunogenicity of the genetically engineered (Pf GAP3KO) sporozoites in human volunteers. Pf GAP3KO sporozoites were delivered to 10 volunteers using infected mosquito bites with a single exposure consisting of 150 to 200 bites per subject. All subjects remained blood stage-negative and developed inhibitory antibodies to sporozoites. GAP3KO rodent malaria parasites engendered complete, protracted immunity against infectious sporozoite challenge in mice. The results warrant further clinical testing of Pf GAP3KO and its potential development into a vaccine strain.
MA01.09 Mortality, Survival and Incidence Rates in the ITALUNG Randomised Lung Cancer Screening Trial (ITALY)
Authors: Eugenio Paci, Donella Puliti, Andrea Lopes Pegna, Laura Carrozzi, Giulia Picozzi, Fabio Falaschi, Francesco Pistelli, Ferruccio Aquilini, Marco Zappa, Francesca Carozzi, Mario Mascalchi
Journal: Journal of Thoracic Oncology (2017)
Prognostic Value of the Different MMSET Gene Breakpoints and Correlation with Immunoglobulin Isotype and FGFR3 Expression in 173 Patients with t(4;14) Multiple Myeloma
Authors: Bertrand Arnulf, Anne Lazareth, Jean Soulier, Stephanie Harel, Lionel Karlin, Damien Roosweil, Karim Belhadj, Jerome Tamburini, Arnaud Jaccard, Raphael Szalat, Bouchra Asli, Marion Malphettes, jean Christophe Bories, Jean Paul Fermand
Journal: Blood (2012)
Anaplastic Variant of Diffuse Large B-Cell Lymphoma: Re-Apprasial As Extra-Mediastinal Grey Zone Lymphoma Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma,
Authors: Nirmeen Ali Megahed, Seiichi Kato, Naoko Asano, Shigeo Nakamura
Journal: Blood (2011)
P60 Effect of Indacaterol/Glycopyrronium (IND/GLY) on patient-reported outcomes in men and women with COPD: a pooled analysis from the ignite programme
Authors: K Kostikas, I Tsiligianni, S Fucile, K Mezzi, S Shen, D Banerji, R Fogel
Journal: Thorax (2016)

<h3>Introduction</h3> Literatures, although limited, suggest differences in the manifestations of COPD in terms of symptoms and health-related quality of life between men and women. Moreover, a pooled analysis of 6 randomised trials from the IGNITE programme showed a lower baseline dyspnoea index (greater dyspnoea) and higher baseline St. George’s Respiratory Questionnaire (SGRQ) total scores (worse health related quality of life) in women compared with men<sup>1</sup>. Here, we report the treatment impact in patient-reported outcomes (PROs) in men and women by further investigating data from the aforementioned pooled analysis. <h3>Methods</h3> Six trials of 24 to 62 weeks duration (ENLIGHTEN, SHINE, ILLUMINATE, ARISE, SPARK and LANTERN) from the IGNITE programme were included. Effects of IND/GLY on PROs, such as transition dyspnoea index (TDI) and SGRQ total scores, symptoms scores via electronic diary and rescue medication use, were assessed, compared with salmeterol/fluticasone (SFC), glycopyrronium (GLY), tiotropium (TIO) and placebo (PBO) in both men and women with moderate to very severe COPD. <h3>Results</h3> Data from 6108 patients were pooled and analysed (men, n = 4719; women, n = 1389). Overall, IND/GLY showed better improvement in dyspnoea and health status at Week 26 compared with other treatments. Although, there was some variability, the effect size was generally larger in women compared with men (Table). In addition, a higher percentage of women than men treated with IND/GLY achieved the minimal clinically important difference (MCID) from baseline in TDI and SGRQ total scores versus other comparators. Similarly, there was a greater reduction of rescue medication use in women than in men that received IND/GLY versus other treatments (Table). The reduction of symptom scores in the e-Diary with IND/GLY was comparable in both genders (Table). <h3>Conclusions</h3> IND/GLY demonstrated superior improvement in dyspnoea and health status in both men and women with COPD compared with SFC, GLY, TIO and PBO. Furthermore, the efficacy of IND/GLY in terms of PROs was found to be better in women than in men and IND/GLY could be considered as a start-up treatment vs monotherapy for women with COPD. If confirmed in further studies these data may support gender differences in PROs response to bronchodilator therapy. <h3>Reference</h3> Fucile S, <i>et al</i>. <i>Am J Respir Crit Care Med</i> 2016;<b>193</b>:A6781.
Abstract A01: Centrosome amplification induces autophagy and sensitizes to chloroquine
Authors: Ryan A. Denu, Mark E. Burkard
Journal: Clinical Cancer Research (2017)

Abstract Autophagy is a catabolic process whereby autophagosomes engulf damaged organelles and proteins and deliver these contents to the lysosome for degradation and subsequent recycling. Proper autophagosome fusion with lysosomes depends on movement along intact microtubules, which are organized by centrosomes in human cells. We have discovered that autophagy is activated by centrosome amplification (CA), a numerical increase in centrosome number. CA is common in human cancers, particularly high-risk cancers, and higher autophagy is predicted to sensitize cancer cells with CA to autophagy inhibition. To test this hypothesis, we first evaluated autophagy in 341 human breast cancers with known CA status by quantifying p62/SQSTM1. Cancers with CA demonstrated a decrease in p62 expression, consistent with elevated autophagy. Next, we evaluated autophagy using western blot and immunofluorescence in two model cell lines of CA: doxycycline-inducible expression of polo-like kinase 4 (PLK4), an enzyme required for centrosome duplication. Cells with CA demonstrated elevated levels of autophagy by LC3 and p62 immunoblotting and immunofluorescence. Third, we tested autophagy inhibitors in our cell models of CA. Our results show that cells with CA are sensitized to the autophagy inhibitor chloroquine. Taken together, our results suggest that autophagy is upregulated by CA. We hypothesize that CA induces autophagy by increasing the number of lysosomal hubs (lysosomes tend to cluster around centrosomes) and facilitating transport to these hubs. These findings suggest CA as a biomarker for autophagy inhibition in high-risk cancers. Citation Format: Ryan A. Denu, Mark E. Burkard. Centrosome amplification induces autophagy and sensitizes to chloroquine. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr A01.
P204 Quality improvement project for emergency oxygen delivery on a respiratory ward
Authors: KE Hutchinson, S Craik, K Srinivasan, H Moudgil, N Ahmad
Journal: Thorax (2016)

<h3>Background</h3> British Thoracic Society (BTS) guidelines state that oxygen should be used to treat hypoxaemia and prescribed to a target saturation range.<sup>1</sup> Patients at risk of type 2 respiratory failure should target 88–92%, with the rest 94–98%. In the BTS national audit in 2013, out of 6214 patients, 55% had oxygen prescribed and 52% were prescribed and delivered to within a target saturation range.<sup>2</sup> <h3>Methods</h3> We ran a Quality Improvement Project (QIP) involving three PDSA cycles to improve the delivery of oxygen to patients on the Respiratory Ward at the Princess Royal Hospital, Telford. We set our standards as: 90% of patients receiving oxygen have it prescribed on a drug chart 100% of patients prescribed oxygen have a documented target saturation range 100% of patients have oxygen delivered appropriately to target The QIP process commenced in Autumn 2015. After the first cycle we used bedside prompt cards and delivered teaching sessions with doctors, nurses and healthcare assistants (HCAs). After the second cycle we appointed a nurse, HCA and two FY1 doctors as <b><i>‘O2 Ninjas’</i></b>. Data were collected at three points after each cycle from drug charts and VitalPaC. <h3>Results</h3> See Table <h3>Conclusions</h3> Our QIP shows that education and empowerment of ‘grass root’ healthcare workers can improve oxygen prescription on a Respiratory ward. We suggest this QIP is replicated in other trusts and specialties to improve safe oxygen delivery. <h3>References</h3> O’Driscoll BR, Howard LS, Davison AG. BTS guideline for emergency oxygen use in adult patients. <i>Thorax</i> 2008;<b>63</b>(Suppl VI):vi1–vi68. BTS Oxygen Audit 2013. https://www.brit-thoracic.org.uk/document-library/audit-and-quality-improvement/audit-reports/bts-emergency-oxygen-audit-report-2013/(accessed 21 January 2016).
Despite Absence of Measurable Immune Responses against Adenovirus in the First 100 Days After Unrelated Umbilical Cord Blood Transplant in Vitro amplification Strategies Can Unveil Hexon and Penton-Specific Immunity.
Authors: Ann M. Leen, Anne Christin, Luciana C Marti, Jennifer H Baker, Paul Szabolcs
Journal: Blood (2009)
Impact of STI571 (Imatinib) on the Pharmacokinetics and In Vivo Efficacy of Etoposide and/or Ifosfamide.
Authors: Keyvan Rezai, François Lokiec, Isabelle Grandjean, Sophie Weill, Patricia de Cremoux, Philippe Arnaud, Vincent Bordier, Richard Ekue, Mickael Garcia, Rosette Lidereau, Marie-France Poupon, Didier Decaudin
Journal: Blood (2006)
P2.03a-070 A Feasibility Study of Adjuvant Chemotherapy with Modified Weekly Nab-Paclitaxel and Carboplatin for Completely Resected NSCLC
Authors: Hisashi Saji, Hiroki Sakai, Yukihiro Kimura, Tomoyuki Miyazawa, Haruhiko Nakamura, Hideki Marushima
Journal: Journal of Thoracic Oncology (2017)
High-Resolution, Genome Wide Analysis of DNA Methylation Provides Insights Into the Epigenetic Architecture of t(4;14) Myeloma.
Authors: Martin F Kaiser, Brian A Walker, Christopher P Wardell, Fabio Mirabella, Rosemary A Fryer, David C Johnson, Kerry Fenwick, Iwanka Kozarewa, Faith E. Davies, Gareth J. Morgan
Journal: Blood (2012)
IL-17-Producing T Cells Contribute to Mediate Acutegraft-Versus-Disease In Patients Undergoing Unmanipulated Blood and MarrowTransplantation
Authors: Xiang-Yu Zhao, Ling-Ling Xu, Sheng-Ye Lu, Kai-Yan Liu, Lan-Ping Xu, Dai-Hong Liu, Xiao Jun Huang
Journal: Blood (2010)